Lyell Immunopharma, Inc.

LYEL

Pharmaceutical Preparations

Mkt Cap

$699.2M

PE

-3.06

Debt

Cash

$125.9M

EV

FCF

-$160.7M

Market Cap

$699.2M

P/E Ratio

-3.06

Debt

Cash

$125.9M

EV

FCF

-$160.7M

Charts data: {"Earnings":[{"time":"2019-12-30","value":-130521000},{"time":"2020-12-30","value":-208054000},{"time":"2021-12-30","value":-250219000},{"time":"2022-12-30","value":-183118000},{"time":"2023-12-30","value":-234632000}],"Sales":[{"time":"2019-12-30","value":657000},{"time":"2020-12-30","value":7756000},{"time":"2021-12-30","value":10650000},{"time":"2022-12-30","value":84683000},{"time":"2023-12-30","value":130000}],"Net Margins":[{"time":"2019-12-30","value":-198.662100456621},{"time":"2020-12-30","value":-26.82490974729242},{"time":"2021-12-30","value":-23.494741784037558},{"time":"2022-12-30","value":-2.162393868899307},{"time":"2023-12-30","value":-1804.8615384615384}],"Assets":[{"time":"2020-12-30","value":908280000},{"time":"2021-12-30","value":1127406000},{"time":"2022-12-30","value":937561000},{"time":"2023-12-30","value":750029000}],"Stockholders Equity":[{"time":"2019-12-30","value":-111108000},{"time":"2020-12-30","value":-292528000},{"time":"2021-12-30","value":929787000},{"time":"2022-12-30","value":833252000},{"time":"2023-12-30","value":654952000}],"ROE":[{"time":"2019-12-30","value":1.174721892212982},{"time":"2020-12-30","value":0.7112276431657825},{"time":"2021-12-30","value":-0.2691143240333539},{"time":"2022-12-30","value":-0.21976304887357007},{"time":"2023-12-30","value":-0.3582430468186982}],"ROA":[{"time":"2020-12-30","value":-0.2333388382437134},{"time":"2021-12-30","value":-0.190504574217274},{"time":"2022-12-30","value":-0.19951555152144768},{"time":"2023-12-30","value":-0.32933126585772016}]}

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Sector

10-Q
9/30/23
10-Q
6/30/23
10-Q
3/31/23
10-K
12/31/22
10-Q
9/30/22
10-Q
6/30/22
10-Q
3/31/22
10-K
12/31/21
10-Q
9/30/21
10-Q
6/30/21

Chart P/E ratio

In the chart Earnings are multiplied by this value.

Earnings Growth -

Earnings Stability -

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

The Net Margin is too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Data are missing

Years	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Net Margin	-20K%	-2.7K%	-2.3K%	-220%	-180K%	-340K%
ROA	-	-23%	-19%	-20%	-33%	-35%
ROE	120%	71%	-27%	-22%	-36%	-38%

What is the average Net Margin?

The average Net Margin over the past 5 years is -180.49K%.

What is the trend of Net Margin?

The trend of Net Margin over the past 5 years is -.

What is the average Return on Assets (ROA)?

The average ROA over the past 5 years is -32.93%.

What is the trend of Return on Assets (ROA)?

The trend of ROA over the past 5 years is -.

What is the average Return on Equity (ROE)?

The average ROE over the past 5 years is -35.82%.

What is the trend of Return on Equity (ROE)?

The trend of ROE over the past 5 years is -.

Safety & Stabiliy

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Data are missing

Years	12-2019	12-2020	12-2021	12-2022	12-2023	TTM
Debt FCF	-	-	-	-	-	-
Debt Equity	-	-	-	-	-	-
MIN
Graham Stability	-	-	-	-	-	-

What is the Debt/FCF?

The Debt/FCF trailing twelve month is -.

What is the trend of Debt/FCF?

The trend of Debt/FCF over the past 5 years is -.

What is the Graham’s Stability?

Graham’s Stability measure stands at -.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Data are missing

Years	12-2020	12-2022	Trend
Revenue	-74%	-100%	-290%
Net Income	-	-	-
Stockholders Equity	-	-21%	-11%
FCF	-	-	-

What is the 5 year Revenue CAGR?

The Revenue CAGR over the past 5 years is -.

What is the trend of Revenue growth?

The trend of Revenue growth rate over the past 5 years is -288.33%.

What is the 5 year Earnings CAGR?

The Earnings CAGR over the past 5 years is -.

What is the trend of Earnings growth?

The trend of Earnings growth rate over the past 5 years is -.

What is the 5 year Equity CAGR?

The Equity CAGR over the past 5 years is -.

What is the trend of Equity growth?

The trend of Equity growth rate over the past 5 years is -11.02%.

What is the 5 year FCF CAGR?

The FCF CAGR over the past 5 years is -.

What is the trend of FCF growth?

The trend of FCF growth rate over the past 5 years is -.